$60,000 of CARDINAL HEALTH INC. lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"General issues affecting the health care industry such as drug pricing, pharmaceutical drugs, medical devices, workforce shortages, and product shortages. Pharmaceutical tariffs"
You can find more data on corporate lobbying on Quiver Quantitative.
CAH Insider Trading Activity
CAH insiders have traded $CAH stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $CAH stock by insiders over the last 6 months:
- AARON E ALT (Chief Financial Officer) sold 2,328 shares for an estimated $524,964
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
CAH Hedge Fund Activity
We have seen 638 institutional investors add shares of CAH stock to their portfolio, and 566 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP removed 890,535 shares (-17.2%) from their portfolio in Q1 2026, for an estimated $186,193,057
- HOLOCENE ADVISORS, LP removed 766,704 shares (-77.5%) from their portfolio in Q1 2026, for an estimated $160,302,472
- 1832 ASSET MANAGEMENT L.P. added 743,196 shares (+37159.8%) to their portfolio in Q1 2026, for an estimated $155,387,419
- BESSEMER GROUP INC added 739,553 shares (+7053.4%) to their portfolio in Q1 2026, for an estimated $154,625,741
- AMERIPRISE FINANCIAL INC added 721,151 shares (+88.1%) to their portfolio in Q1 2026, for an estimated $150,778,251
- AUSTRALIANSUPER PTY LTD removed 602,513 shares (-78.8%) from their portfolio in Q1 2026, for an estimated $125,973,418
- BRANDES INVESTMENT PARTNERS, LP removed 523,985 shares (-67.0%) from their portfolio in Q1 2026, for an estimated $109,554,783
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
CAH Analyst Ratings
Wall Street analysts have issued reports on $CAH in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- William Blair issued a "Outperform" rating on 04/28/2026
- Morgan Stanley issued a "Overweight" rating on 01/29/2026
To track analyst ratings and price targets for CAH, check out Quiver Quantitative's $CAH forecast page.
CAH Price Targets
Multiple analysts have issued price targets for $CAH recently. We have seen 9 analysts offer price targets for $CAH in the last 6 months, with a median target of $245.0.
Here are some recent targets:
- Charles Rhyee from TD Cowen set a target price of $275.0 on 07/09/2026
- Allen Lutz from B of A Securities set a target price of $260.0 on 07/02/2026
- Lisa Gill from JP Morgan set a target price of $215.0 on 05/04/2026
- Stephen Baxter from Wells Fargo set a target price of $245.0 on 05/01/2026
- Daniel Grosslight from Citigroup set a target price of $245.0 on 05/01/2026
- Elizabeth Anderson from Evercore ISI Group set a target price of $240.0 on 04/08/2026
- Glen Santangelo from Barclays set a target price of $258.0 on 02/24/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
